Curalogic updates from its Phase III clinical study with the ragweed product

Announcement no. 21/2007                                                        


To the OMX Nordic Exchange                                         
Copenhagen, 
November 5, 2007                                                                






Curalogic updates from its Phase III clinical study with the ragweed product    

Summary: All patients in Curalogic's Phase III clinical study with the ragweed  
product have now completed the planned treatment. The next steps are first      
quality control of all data and then calculation of the results of the study.   
Curalogic plans to publish results from the study in the first quarter of 2008. 

As planned, Curalogic has completed the dosing of patients in the Phase III     
clinical study (RPE 04) with the product for the treatment of ragweed allergy.  
In the upcoming period, data from the study will be subjected to quality control
and collected in a database. The study is blinded during the entire process,    
meaning that neither the doctors nor the persons in charge of quality control   
know which patients have received active treatment and which have received      
placebo. Work will now begin to calculate the results and conduct quality       
control to ensure that the calculations are correct, and only after completion  
of these procedures will Curalogic be ready to release the results. Curalogic   
expects to publish the results from the study in the first quarter of 2008 and  
plans to file a registration application for the ragweed product in Europe in   
the second half of 2008.                                                        

Design of the Phase III clinical study                                          
Dr. Peter Creticos, Medical Director of the Johns Hopkins Asthma and Allergy    
Center, is the principal investigator of the RPE 04 study. RPE 04 is a          
double-blinded, randomized placebo-controlled study. The study objective is to  
evaluate the effect and safety of a daily dose of orally administered ragweed   
pollen extract to patients suffering from ragweed allergy. The study includes   
545 patients with moderate to severe ragweed allergy in the United States,      
Italy, Hungary and Serbia.                                                      

Curalogic's product for the treatment of ragweed allergy                        
In addition to the RPE 04 study, the ragweed product has been thoroughly tested 
in seven completed clinical studies involving more than 1,000 patients. The     
results from the clinical studies have shown the same good reduction of allergy 
symptoms as achieved with injection-based immunotherapy, and that the product is
safe and has very few adverse effects.                                          

Ragweed allergy                                                                 
In Denmark, ragweed is called Bynke-ambrosie. About 4 million people in Europe  
and 29 million people in the United States suffer from ragweed allergy. Patients
experience ragweed allergy as one of the worst allergies. This is partly due to 
the fact that pollen from ragweed is very potent and partly that the pollen     
season is very long (6-8 weeks).                                                


Yours sincerely                                                                 

Curalogic A/S                                                                   


For additional information, please contact:                                     
Peter Moldt, President and CEO	Phone +45 99 99 24 00, mobile +45 26 25 04 22    
Helle Busck Fensvig, EVP and CFO 	Pnone +45 99 99 24 00, mobile +45 20 70 55 37 

About Curalogic                                                                 
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic        
Exchange (CUR.CO) as a small cap + company. Curalogic develops innovative       
products for the treatment of allergy using a patented formulation technology.  
The products combine the efficacy of immunotherapy with the patient friendliness
of antihistamines and have the potential to become the preferred type of allergy
treatment among patients. Curalogic has a broad and mature pipeline with a      
product for the treatment of ragweed allergy in Phase III, a product for the    
treatment of grass allergy ready for Phase III, a product for the treatment of  
cat allergy in Phase II and a product for the treatment of house dust mite      
allergy being prepared for clinical trials.                                     












































This announcement contains forward-looking statements regarding the Company's   
future financial development and performance and other statements which are not 
historical facts. Such statements are made on the basis of assumptions and      
expectations which, to the best of the Company's knowledge and belief, are      
reasonable, at this time, but may prove to be erroneous in the future.